Show simple item record

dc.contributor.authorMarme, F.
dc.contributor.authorWildiers, H.
dc.contributor.authorDirix, L.
dc.contributor.authorArmstrong, Anne C
dc.contributor.authorDe Cuypere, E.
dc.contributor.authorDalenc, F.
dc.contributor.authorSchroder, C. P.
dc.contributor.authorVuylsteke, P.
dc.contributor.authorBrain, E.
dc.contributor.authorKuemmel, S.
dc.contributor.authorPapai, Z.
dc.contributor.authorMueller, C.
dc.contributor.authorBrignone, C.
dc.contributor.authorTriebel, F.
dc.date.accessioned2022-06-22T07:18:38Z
dc.date.available2022-06-22T07:18:38Z
dc.date.issued2022en
dc.identifier.citationMarmé F, Wildiers H, Dirix L, Armstrong A, De Cuypere E, Dalenc F, et al. 171P Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast cancer. Vol. 33, Annals of Oncology. Elsevier BV; 2022. p. S203–4.en
dc.identifier.doi10.1016/j.annonc.2022.03.190en
dc.identifier.urihttp://hdl.handle.net/10541/625346
dc.description.abstractBackground Eftilagimod alpha (EF) is a soluble LAG-3 protein (LAG-3Ig) that binds to a subset of MHC class II molecules and mediates activation of antigen-presenting cells followed by T-cells. AIPAC investigated EF + paclitaxel (PA). We hereby report exploratory biomarker and multivariate analyses. Methods This double-blinded, 1:1 randomized phase IIb trial enrolled pts with HR+ HER2- MBC. Pts received PA (80 mg/m2 IV on D1, D8, D15) + EF (30 mg) or placebo (PL) on D2, D16 per cycle (28 days) for 24 wks + EF/PL for 52 wks. Exploratory EPs were potential biomarkers and their correlation to efficacy. Multivariate analysis used backward selection p>0.15 (univariate cox model). Blood cell subsets (CD4; CD8, PBMCs, monocytes) & Th1 biomarker CXCL-10 were measured centrally. Comparison was done using 2-sided Wilcoxon test. Results 226 pts [efti n=114; placebo n=112] were included. Pts were endocrine resistant (84%), pre-treated with CDK4/6 inhibitors (44.2%). Post-study treatment was similar. Safety/efficacy were reported at SABCS 2020 #132; SITC 2021 #948 In the multivariate predictive model 4 groups (high Neutrophil/Lymphocyte Ratio [NLR]; no prior taxanes; low monocytes and <5 yrs since diagnosis) were significant for OS (Table) On treatment mean fold-changes of monocytes (5.81 vs. 2.29; p=0.025), PBMCs (2.00 vs. 1.41; p=0.041), T cells (2.28 vs. 1.48; p=0.086), & CXCL10 (2.78 vs. 1.56; p=0.06) were significantly higher (EF vs PL) and linked to higher OS. Post baseline CD4 (median 896/μl vs. 736 μl; p=0.038) & CD8 (median 377/μl vs. 223 μl; p=0.005) T cell count increased significantly in pts with higher OS EF vs. PL. Conclusions EF + PA elicits significant effects on different immune cells which is significantly associated with higher OS. Multivariate analysis identified potential target populations for phase III.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2022.03.190en
dc.titleBiomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs placebo in combination with weekly paclitaxel in HR+HER2-metastatic breast canceren
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedical Faculty, University Hospital Mannheim, Heidelberg University, Mannheim, Germanyen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record